Can you take Wegovy forever? What the evidence and your licence actually say

The myth that Wegovy is a short course — and what's true instead

The most common misconception is that Wegovy is prescribed the way antibiotics are: a fixed course, then done. That is not how it works. Semaglutide reduces appetite by activating GLP-1 receptors involved in hunger signalling. When the medicine leaves your system, those signals return to their previous state. Clinical trial data published in the STEP 1 study in the New England Journal of Medicine showed that participants who stopped semaglutide after 68 weeks regained most of the weight they had lost within about a year. That is not a side effect of the medicine, it reflects the underlying biology of obesity as a chronic condition.

So calling Wegovy a "course" misframes it. For many people, weight management with a GLP-1 medicine is closer to managing blood pressure with medication: effective while taken, with the condition reasserting itself once it is not. None of that means you will take it forever. It means the question of duration deserves a proper clinical conversation rather than a blanket time limit.

Whether you are wondering about this at the six-month mark or have been on treatment for longer, the key considerations around Wegovy suitability do not change: continuing benefit, tolerability, and your wider health picture all matter.

What the NHS two-year rule actually means, and what it does not

NICE's appraisal of semaglutide (TA875) recommends it for use within a specialist weight management service for a maximum of two years. That cap applies specifically to NHS commissioning. It reflects how the technology appraisal was scoped, not a clinical finding that the medicine becomes unsafe or ineffective after 24 months. NICE TA875 also advises that continuing should be reviewed if weight loss is below 5% at six months on the maintenance dose, a threshold that applies throughout treatment, not just at the two-year point.

Private patients are not subject to the NHS two-year cap. A GPhC-registered prescriber working through a regulated pharmacy can, in principle, continue to prescribe Wegovy beyond two years, provided they review the clinical case before each repeat. At nume, that review happens before every order, a named clinician reads your information, not software. There are no auto-renewals. That structure matters for long-term use precisely because your health context can change: new medicines, a pregnancy test, a change in BMI, a new diagnosis. Each of those could affect whether continuing is appropriate.

If you are weighing up the cost of ongoing private treatment, it is worth factoring in what that clinical oversight includes, not just the sticker price.

What stopping looks like, and who should guide it

Some people reach a stable weight and choose to stop. Some switch medicines. Some pause for practical reasons, a planned pregnancy, a surgical procedure, a holiday where keeping injections refrigerated felt too complicated (a Monday order before a fortnight away is a question our prescribers field regularly). Whatever the reason, stopping should be a planned decision made with your prescriber, not something that happens because a repeat gets missed.

The NHS medicines page for semaglutide notes that weight management with this medicine works best alongside sustained changes to diet and activity. Patients who have built those habits during treatment tend to maintain more of their results after stopping than those who relied on the medicine alone. That is not a guarantee (biology still asserts itself) but it is a meaningful difference. Your prescriber can help you plan a realistic exit strategy if and when that becomes relevant, including whether a gradual approach makes more sense than stopping abruptly.

For practical questions about injection timing and scheduling, you may find the guidance on dose spacing useful context. Eligibility for starting or continuing treatment, including where the Wegovy BMI cutoff sits and how it is applied, is explained on the BMI requirements page.

The clinical review before every repeat: why it matters for long-term users

Long-term use raises questions that a one-time assessment cannot cover. Has your BMI changed enough to affect the risk-benefit calculation? Have you started a new medicine that interacts with semaglutide's effects on gastric emptying? Is there any new reason (a planned operation, a change in family planning) that means a pause is clinically sensible? These are not bureaucratic hurdles. They are the reason that ongoing prescribing requires ongoing review.

At nume, our clinical team reviews every repeat before it is dispensed, the same standard applies to your first order and your twelfth. If you have a question between orders, our aftercare team is available seven days a week. Wegovy is a prescription-only medicine; suitability is not a one-time verdict. It is a living clinical assessment. If you are ready to start that process, or want to move your existing treatment to a pharmacy that takes this approach, you can start your free consultation and hear from a prescriber the same day.